AI-powered platform for mapping the gut-immune axis for medicines. AI-powered platform for mapping the gut-immune axis for medicines. The company uses artificial intelligence and synthetic biology for mining the gut microbiome for small molecules to treat immunological disorders and advance immunotherapy. Founded in 2018, headquartered in San Francisco, United States. The company has raised $15. The company operates in the HealthTech > Life Sciences Tech, Life Sciences > Life Sciences Tech sector. Founded in 2018 and headquartered in San Francisco, United States and has raised $15.0 million in Series A funding. Key investors include Viking Global Investors, Merck Global Health Innovation Fund, CJ Investment, The Venture Collective, Joyance Partners, Good AI Capital, Iaso Ventures, Neue Fund.
Pragma Bio
Series AAI-powered platform for mapping the gut-immune axis for medicines. AI-powered platform for mapping the gut-immune axis for medicines. The company uses artificial intelligence and synthetic biology for mining the gut microbiome for small molecules to treat immunological disorders and advance immunotherapy. Founded in 2018, headquartered in San Francisco, United States. The company has raised $15. The company operates…
About
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based
Founders & team highlights
Serial Founder
Team background
Company Wise > Google,
College Wise > Harvard University, Duke University
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.